Home › Research › Drug development
The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses
Ballum H, Dri C, Liao S, Yu M, Le GH, Wong S, Teopiz KM, Kwan ATH et al.. Journal of affective disorders, 2026-01-30
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Results from extant studies indicate that type 2 diabetes mellitus (T2DM) is associated with decreased cognitive function and increased risk for dementia, notably Alzheimer's Disease (AD). Herein, we aimed to evaluate the effect of glucacon-like peptide-1 receptor agonists (GLP-1 RAs) on cognitive measures in persons with cognitive impairment and T2DM from available systematic reviews and meta-analyses. Methods A literature search was conducted using Web of Science and MEDLINE from inception to July 15, 2025. Article screening and data extraction were conducted by three reviewers (H.B., C.D., S.L.). Primary research studies examining race, sex, children, animals and neurodegenerative diseases other than AD were excluded. Results Nine systematic reviews and meta-analyses examining the effect of GLP-1 RAs on cognitive function in adults with T2DM were included. Evidence suggests that GLP-1 RAs are associated with a reduction in overall cognitive decline in adults with T2DM and dementia/AD. Replicated findings from meta-analyses indicated that GLP-1 RAs improved performance on cognitive assessments (total learning; p = 0.039; p < 0.00001). Some meta-analyses observed a change in cognitive measures but lacked sufficient statistical significance (p > 0.05). Conclusions GLP-1 RAs positively affect cognitive function in AD patients with T2DM. However, their efficacy on disparate cognitive domains requires further replication in larger scale controlled clinical trials.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ballum, H., Dri, C., Liao, S., Yu, M., Le, G. H., Wong, S., et al. (2026). The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses. Journal of affective disorders. https://doi.org/10.1016/j.jad.2026.121310
Vancouver
Ballum H, Dri C, Liao S, Yu M, Le GH, Wong S, et al. The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses. Journal of affective disorders. 2026. doi:10.1016/j.jad.2026.121310. PMID: 41621451.
BibTeX
@article{ballum2026-41621451,
author = {Ballum, H. and Dri, C. and Liao, S. and Yu, M. and Le, G. H. and Wong, S. and Teopiz, K. M. and Kwan, A. T. H. and others},
title = {{The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses}},
journal = {Journal of affective disorders},
year = {2026},
doi = {10.1016/j.jad.2026.121310},
pmid = {41621451},
url = {https://doi.org/10.1016/j.jad.2026.121310}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Background Results from extant studies indicate that type 2 diabetes mellitus (T2DM) is associated with decreased cognitive function and increased risk for dementia, notably Alzheimer's Disease (AD).
- Results Nine systematic reviews and meta-analyses examining the effect of GLP-1 RAs on cognitive function in adults with T2DM were included.
- Evidence suggests that GLP-1 RAs are associated with a reduction in overall cognitive decline in adults with T2DM and dementia/AD.
- Replicated findings from meta-analyses indicated that GLP-1 RAs improved performance on cognitive assessments (total learning; p = 0.039; p < 0.00001).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Evidence strengthHigh
How this study scored 71/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 41 of the 58 points we could judge it on, which is 71 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of affective disorders) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41621451) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 41 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 41 of the 58 points we could judge it on is 71 out of 100. |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “reviews”
4 studies in the library carry the topic tag “reviews”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.